LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Roivant Sciences Ltd

Roivant Sciences Ltd

Chiusa

SettoreSettore sanitario

29.52 2.86

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.65

Massimo

29.63

Metriche Chiave
By Trading Economics
Entrata	669M 356M
Vendite	521K 2.5M
Margine di Profitto	14,116.825
Dipendenti	721
EBITDA	-65M -354M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.91% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	32M 20B
Apertura precedente	26.66
Chiusura precedente	29.52

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 giu 2026, 21:51 UTC

I principali Market Mover

Merlin Shares Rally After Defense Department's Design Review Wraps

4 giu 2026, 23:46 UTC

Discorsi di Mercato

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 giu 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 giu 2026, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 giu 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 giu 2026, 23:34 UTC

Discorsi di Mercato

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

4 giu 2026, 23:08 UTC

Discorsi di Mercato

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 giu 2026, 22:41 UTC

Discorsi di Mercato

Australia Shares Set to Rise at the Open -- Market Talk

4 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 giu 2026, 20:16 UTC

Discorsi di Mercato

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 giu 2026, 19:46 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 giu 2026, 19:38 UTC

Discorsi di Mercato

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 giu 2026, 19:30 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 giu 2026, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 giu 2026, 18:38 UTC

Utili

Money Quote: Tech Weakness in Context -- WSJ

4 giu 2026, 18:24 UTC

Utili

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 17:09 UTC

Discorsi di Mercato

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 giu 2026, 16:58 UTC

Utili

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 16:46 UTC

Discorsi di Mercato

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 giu 2026, 16:38 UTC

Utili

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

4 giu 2026, 16:13 UTC

Discorsi di Mercato

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 giu 2026, 16:11 UTC

Discorsi di Mercato

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 giu 2026, 15:56 UTC

Discorsi di Mercato

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

33.91% in crescita

Previsioni per 12 mesi

Media 37.83 USD 33.91%

Alto 42 USD

Basso 31.5 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.